So-called "functional" mushrooms are generating a real buzz in Europe, and it's no coincidence. Reishi, lion's mane, and cordyceps are often touted as allies for well-being, concentration, energy, and overall balance. But when you move beyond the marketing hype and look at recent scientific publications, the picture becomes more nuanced, and frankly, more interesting.
In 2025 and 2026, the overall trend remains the same: there is biologically plausible potential for these three species, but robust clinical evidence in humans remains limited. In other words, research is progressing, some signals are promising, but we must avoid oversimplification. Here's what the research reveals about reishi, lion's mane , and cordyceps, with a clear, energetic, and data-driven perspective.
Lion's mane: the most closely watched mushroom for cognition
Lion's mane, or Hericium erinaceus, is probably the most publicized of the three when discussing the brain, concentration, and mood. This reputation is partly based on bioactive compounds that interest researchers for their potential mechanisms at the neuronal level, particularly in the field of neuroprotection.
A 2025 randomized, double-blind, placebo-controlled clinical trial evaluated a standardized lion's mane extract in healthy young adults. The fact that this study is recent, published in 2025 and indexed on PubMed, is an important signal: human research continues to progress and is beginning to test more rigorous protocols on cognition and mood.
Meanwhile, a narrative review published in 2025 in Nutrients concluded that the bioactive compounds of H. erinaceus are associated with antioxidant, anti-inflammatory, and antimicrobial effects. This reinforces scientific interest in the fungus, while also highlighting a crucial point: these findings are encouraging, but they do not replace large, standardized clinical trials.
Human results still uneven for the lion's mane
Looking closely at the clinical trials already available, the results of lion's mane remain mixed. A 2023 pilot trial studied the acute and chronic effects of supplementation on cognitive function, stress, and mood in young adults. This type of work provides useful insights, but it remains limited by sample sizes and the variability of protocols.
Another 2022 trial reported that a 4-week course of supplementation did not improve markers of metabolic flexibility or cognition. This type of result is important because it shows that the enthusiasm surrounding lion's mane should not lead to overestimating its effectiveness in all contexts or for all profiles.
Recent reviews converge on a simple idea: the signal of efficacy for lion's mane is currently primarily preclinical. Much of the data comes from animal studies or cellular mechanisms, while clinical consensus in humans is not yet established. In practice, this means that lion's mane remains interesting, but is still far from being definitively validated for cognition in the medical sense of the term.
Reishi: a solid tradition, clinical validation still under construction
Reishi, or Ganoderma lucidum, has a very long history of traditional use, particularly in Chinese medicine. In 2025, several journals reviewed its pharmacology and described a mushroom rich in bioactive metabolites, with broad potential scientific applications.
Among the most frequently cited potential benefits of reishi are immunomodulatory, anti-inflammatory, and metabolic activities. A 2025 review focusing on bioactive compounds and pharmacological effects effectively summarizes the current state of the literature: there is a wealth of preclinical data, but it is crucial to clearly distinguish this level of evidence from effects that have been definitively confirmed in humans.
In other words, reishi remains one of the most fascinating mushrooms to study, but also one of the easiest to idealize. There's still a hurdle to overcome between its potential measured in the laboratory and its clinically proven benefits in adults. This is precisely what the most recent publications show.
Reishi and clinical trials: a great deal of heterogeneity
A GRADE systematic review and meta-analysis, published or recently indexed in 2025 and searching for trials up to August 2024, examined clinical studies on Ganoderma lucidum. Its main finding is very clear: the results are highly heterogeneous, which complicates definitive conclusions.
This heterogeneity affects several dimensions: populations studied, doses used, duration of supplementation, criteria measured, and quality of extracts. A 2025 review on the clinical application of reishi also highlights that, even in areas often emphasized such as blood glucose, clinical data remain variable and sometimes difficult to compare.
For the reader, the useful message is simple: reishi is not an ingredient without merit, but human studies have not yet demonstrated consistent and robust effects. Therefore, claims should be viewed with a critical eye, keeping in mind that traditional use alone does not constitute modern clinical proof.
Cordyceps: energy and performance, but with still modest evidence
Cordyceps is often associated with endurance, vitality , and supporting physical performance. Indeed, most recent research focuses on this area. In 2025, a review entitled "Ergogenic Aid by Cordyceps: Does It Work?" reassessed the question of its usefulness as an ergogenic aid.
The conclusion is nuanced: cordyceps supplementation may have a more pronounced impact on aerobic performance when combined with other herbs and training. However, the overall evidence remains modest. Therefore, we are far from a strong consensus that would allow us to assert a dramatic effect in all users.
There is also some interesting preclinical data. A 2025 study on cordycepin, a major component of Cordyceps militaris, suggests an anti-fatigue effect in mice using a forced exercise model, with proposed antioxidant and anti-inflammatory mechanisms. This is encouraging from a biological standpoint, but it does not replace robust human trials.
The special case of human studies on cordyceps
Human trials on cordyceps do exist, but they remain relatively few and often outdated. For example, a controlled trial in healthy elderly subjects examined the effect of Cordyceps sinensis in its Cs-4 form on exercise performance. This type of publication shows that the subject is not new, but also that the clinical basis remains rather limited.
The main problem is that these historical studies are insufficient to resolve the issue for today's consumers. The populations studied, the forms used, the performance criteria, and the methodological standards do not always correspond to the current expectations of modern clinical research.
In short, cordyceps remains of real interest to active adults, sports enthusiasts, and those seeking an energy-focused wellness approach. However, at this stage, science speaks more of plausible potential than of firmly proven efficacy. This is an important distinction for informed purchasing .
Why it is so difficult to compare studies
One methodological point that keeps recurring in 2025 reviews is the standardization of extracts, which is a major problem. Studies show that the same part of the mushroom, the same extraction method, and the same compositional markers are not necessarily used. As a result, two products with the same name can be very different in reality.
This lack of harmonization severely limits comparability between trials. When one study observes an effect and another does not, this can be due to the dosage, duration, population studied, but also simply to the quality or nature of the extract. This is one of the reasons why overall conclusions remain cautious regarding reishi, lion's mane, and cordyceps.
Another point to be aware of: product labeling and identity can vary. Recent discussions surrounding reishi highlight that some products sold as Ganoderma lucidum do not always correspond exactly to the advertised species. For consumers, this underscores the importance of choosing tested, traceable, and clearly documented products.
Mixed mushrooms: a real puzzle to interpret the effects
Another challenge in current research is that functional mushrooms are often studied in mixtures rather than individually. For example, a 2025 exploratory study on sleep and mood evaluated a formula containing reishi, lion's mane, and cordyceps. The problem is that a positive or negative result then becomes difficult to attribute to a single species.
For both brands and consumers, these blends may seem appealing because they promise a holistic approach. But from a scientific perspective, they muddy the waters. If the goal is to know precisely what research reveals about reishi, lion's mane, and cordyceps, studies on combined formulas provide useful clues, but don't allow for clear conclusions about each mushroom individually.
This is also why it's crucial to pay close attention to a product's exact composition. Behind seemingly similar marketing claims, the realities can be very different: mushroom alone or blended, fruiting extract or mycelium, clear or unclear standardization, transparent or vague dosage. All these elements are extremely important when trying to connect a commercial product to available scientific data.
In summary, recent research on reishi, lion's mane, and cordyceps confirms one thing above all: these mushrooms have genuine scientific interest, but not yet the level of clinical validation sometimes suggested by marketing claims. Lion's mane is particularly noteworthy for its effects on cognition, reishi for its broad pharmacological profile, and cordyceps for its impact on exercise performance, but for all three, human evidence remains incomplete.
The best approach today is therefore an informed and measured one. Look for traceable, tested, and clearly labeled products, maintain realistic expectations, and clearly distinguish between biological potential and proven benefit. It is precisely in this spirit that reading studies becomes useful: not to believe in miracles, but to make smarter and more transparent choices.
